LYEL - Lyell Immunopharma, Inc.
After hours:
Chart Events
Relative Strength Index (RSI)
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 3.4200 |
| Open | 3.4100 |
| Bid | 3.0600 x 1800 |
| Ask | 4.0000 x 900 |
| Day's Range | 3.3207 - 3.5150 |
| 52 Week Range | 1.7700 - 8.7400 |
| Volume | |
| Avg. Volume | 1,078,622 |
| Market Cap | 856.159M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.9300 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.25 |
Fair Value
Related Research
Simply Wall St.Even after rising 12% this past week, Lyell Immunopharma (NASDAQ:LYEL) shareholders are still down 31% over the past year
Over the last month the Lyell Immunopharma, Inc. ( NASDAQ:LYEL ) has been much stronger than before, rebounding by 54...
ZacksLyell Immunopharma (LYEL) Reports Q1 Loss, Lags Revenue Estimates
Lyell Immunopharma (LYEL) delivered earnings and revenue surprises of 3.57% and 97.40%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswireLyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2023
Two phase 1 clinical trials recruiting patients at 14 sites across the US; nine sites for LYL797, a ROR-1-targeted chimeric antigen receptor T cell (CAR-T) product candidate, and five sites for LYL845, a tumor infiltrating lymphocyte (TIL) product candidateCash, cash equivalents and marketable securities of $668.0 million as of March 31, 2023 support advancing robust pipeline into 2026, through multiple clinical milestones SOUTH SAN FRANCISCO, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Lyell Immun
- GlobeNewswire
Lyell Immunopharma to Participate in BofA Securities Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today announced that members of its senior management team will participate in the BofA Securities 2023 Healthcare Conference on Tuesday, May 9 at 3:00 pm PT. A live webcast of the fireside chat can be accessed through the investor relations section of the Company's websi
- Simply Wall St.
There's No Escaping Lyell Immunopharma, Inc.'s (NASDAQ:LYEL) Muted Revenues
Lyell Immunopharma, Inc.'s ( NASDAQ:LYEL ) price-to-sales (or "P/S") ratio of 7x might make it look like a buy right...
ZacksAurinia (AUPH) Surges 11.0%: Is This an Indication of Further Gains?
Aurinia (AUPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
- Simply Wall St.
Lyell Immunopharma, Inc. (NASDAQ:LYEL) has caught the attention of institutional investors who hold a sizeable 47% stake
Key Insights Given the large stake in the stock by institutions, Lyell Immunopharma's stock price might be vulnerable...
ZacksLyell Immunopharma (LYEL) Reports Q4 Loss, Tops Revenue Estimates
Lyell Immunopharma (LYEL) delivered earnings and revenue surprises of 90.32% and 1,597.76%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022
Cash, cash equivalents and marketable securities of $710.3 million as of December 31, 2022 supports advancing robust pipeline into 2026, through multiple clinical milestonesPhase 1 clinical trials initiated for two wholly-owned product candidates for the treatment of solid tumorsNonclinical data highlighting CAR T cell and TIL product candidates designed for differentiated potency and durability presented at multiple scientific conferences SOUTH SAN FRANCISCO, Calif., Feb. 28, 2023 (GLOBE NEWSWI
- Simply Wall St.
Here's Why We're Not Too Worried About Lyell Immunopharma's (NASDAQ:LYEL) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
- GlobeNewswire
Lyell Immunopharma to Participate in 41st Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, announced today that members of its senior management team will present and participate in the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10 at 4:30 pm Pacific Time. At the conference, Lyell executives will highlight the company’s growing pipeline
- Simply Wall St.
Lyell Immunopharma (NASDAQ:LYEL) investors are sitting on a loss of 63% if they invested a year ago
The nature of investing is that you win some, and you lose some. And unfortunately for Lyell Immunopharma, Inc...
American City Business JournalsLynn Seely steps into top role at cancer-fighting company Lyell Immunopharma
Seely steps into the top operational roles at a company where outgoing president and CEO Liz Homans guided two cancer cell therapies into the clinic.
- GlobeNewswire
Lyell Immunopharma Appoints Lynn Seely, MD as President and Chief Executive Officer
SOUTH SAN FRANCISCO, Calif., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, announced that Lynn Seely, MD, a member of the company’s board and former president and chief executive officer (CEO) of Myovant Sciences, has been named Lyell’s president & CEO effective today. Dr. Seely succeeds Ms. Liz Homans following a four-year tenure as president
ZacksLyell Immunopharma (LYEL) Loses 21.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Lyell Immunopharma (LYEL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
- GlobeNewswire
Lyell Immunopharma to Participate in BofA Securities Biotech Conference
SOUTH SAN FRANCISCO, Calif., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, today announced that members of its senior management team will participate in the virtual BofA Securities 2022 Biotech SMID Cap Conference on Thursday, Dec. 8 at 1:40 pm ET. A live webcast of the fireside chat can be accessed through the investor relations section of t
- Simply Wall St.
Earnings Beat: Lyell Immunopharma, Inc. (NASDAQ:LYEL) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Shareholders in Lyell Immunopharma, Inc. ( NASDAQ:LYEL ) had a terrible week, as shares crashed 20% to US$4.53 in the...
- GlobeNewswire
Lyell Immunopharma to Participate in Barclays Virtual Fireside Chat Series
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, announced today that members of its senior management team will participate in the Barclays Virtual Fireside Chat Series on Thursday, November 17, at 11 a.m., ET. A webcast of the presentation can be accessed through the investor relations section of the Company’s websi
- Simply Wall St.
Lyell Immunopharma Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag
Lyell Immunopharma ( NASDAQ:LYEL ) Third Quarter 2022 Results Key Financial Results Revenue: US$3.0k (down 100% from 3Q...
- Zacks
Lyell Immunopharma (LYEL) Reports Q3 Loss, Lags Revenue Estimates
Lyell Immunopharma (LYEL) delivered earnings and revenue surprises of 17.65% and 99.96%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Lyell Immunopharma Reports Recent Business Highlights and Third Quarter Financial Results
Investigational New Drug (IND) application clearance of LYL845 advances second wholly owned product candidate into clinical developmentCash, cash equivalents and marketable securities of $750.7 million as of September 30, 2022; extends funding into 2026 and supports advancement of multiple product candidates through key clinical milestones SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Lyell) (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company
- GlobeNewswire
Lyell Immunopharma Presents New Data at SITC Highlighting its Growing Pipeline of T – Cell Reprogramming Technologies and Product Candidates Targeting Solid Tumors
Preclinical data demonstrate genetic and epigenetic reprogramming can ameliorate T cell exhaustion and enhance stem-like qualities and potency of T cells in various modalities SOUTH SAN FRANCISCO, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, is presenting preclinical data at the 37th Annual Meeting of the Society for Immunotherapy of
ZacksLyell Immunopharma (LYEL) Expected to Beat Earnings Estimates: Should You Buy?
Lyell Immunopharma (LYEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
Lyell Immunopharma to Participate in Credit Suisse Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, announced today that members of its senior management team will present at the Credit Suisse 31st Annual Healthcare Conference Wednesday, November 9, at 2:00 p.m. ET. A live webcast of the presentation can be accessed through the investor relations section of the Compan
BenzingaGSK Walks Away From T-Cell Therapy Pact With Lyell Citing Strategic Actions
GSK plc (NYSE: GSK) has decided to terminate the License and Collaboration Agreement with Lyell Immunopharma Inc (NASDAQ: LYEL). The termination is effective on December 24. GSK will discontinue its development of product candidates targeting NY-ESO-1, including the second‑generation candidates incorporating Lyell's genetic and epigenetic reprogramming technologies (LYL132 and LYL331), as well as other second-generation approaches GSK was exploring. The FDA cleared LYL132 Investigational New Dru